Human papillomavirus prevalence, persistence and cervical dysplasia in females with cystic fibrosis.


Journal

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966

Informations de publication

Date de publication:
May 2023
Historique:
received: 04 09 2022
revised: 14 11 2022
accepted: 27 11 2022
medline: 12 6 2023
pubmed: 17 12 2022
entrez: 16 12 2022
Statut: ppublish

Résumé

A higher risk of human papillomavirus (HPV)-related cervical intra-epithelial neoplasia (CIN) is suspected among females with cystic fibrosis (CF). We conducted a single center prospective cohort study among females attending the Lyon adult CF center. We performed a cervical cytology (Hologic Thinprep®) and HPV testing with genotyping (Clinical Arrays Papillomavirus; Genomica, enabling 35 genotype detection, 20 of which are high-risk (HR-HPV)) at inclusion. We followed all females with positive HPV tests at 6, 12 and 24 months to evaluate HPV persistence, and performed a colposcopy in cases of abnormal cytology. We included eighty-five participants, 18 (21%) of whom were lung-transplanted. The mean age at inclusion was 31.9 (range 18-59) years. The prevalence of HPV (all types) was 31.8%. HR-HPV was found in 25.9% of the whole cohort, 44.4% of transplanted patients, and 20.1% of nontransplanted patients. Genotype-specific HR-HPV persistence at 12 months was 43.5% among transplanted and 34.6% among nontransplanted patients. Overall, 17.6% (15/85) of females had an abnormal cytology: 44.4% (8/18) among transplanted and 10.4% (7/67) among nontransplanted patients. CIN was identified in 12 (14.1%) patients (6 low-grade, 6 high-grade). High-grade CIN developed in 4 nontransplanted patients. Transplanted females had high HR-HPV, abnormal cervical cytology and CIN prevalence rates compared to large published cohorts in the general non-CF population. Although HR-HPV prevalence and persistence were globally not significantly different in nontransplanted females compared to the general population, we reported high frequencies of abnormal cytology and CIN. Cervical cancer screening and prevention should be promoted among females with CF.

Sections du résumé

BACKGROUND BACKGROUND
A higher risk of human papillomavirus (HPV)-related cervical intra-epithelial neoplasia (CIN) is suspected among females with cystic fibrosis (CF).
METHODS METHODS
We conducted a single center prospective cohort study among females attending the Lyon adult CF center. We performed a cervical cytology (Hologic Thinprep®) and HPV testing with genotyping (Clinical Arrays Papillomavirus; Genomica, enabling 35 genotype detection, 20 of which are high-risk (HR-HPV)) at inclusion. We followed all females with positive HPV tests at 6, 12 and 24 months to evaluate HPV persistence, and performed a colposcopy in cases of abnormal cytology.
RESULTS RESULTS
We included eighty-five participants, 18 (21%) of whom were lung-transplanted. The mean age at inclusion was 31.9 (range 18-59) years. The prevalence of HPV (all types) was 31.8%. HR-HPV was found in 25.9% of the whole cohort, 44.4% of transplanted patients, and 20.1% of nontransplanted patients. Genotype-specific HR-HPV persistence at 12 months was 43.5% among transplanted and 34.6% among nontransplanted patients. Overall, 17.6% (15/85) of females had an abnormal cytology: 44.4% (8/18) among transplanted and 10.4% (7/67) among nontransplanted patients. CIN was identified in 12 (14.1%) patients (6 low-grade, 6 high-grade). High-grade CIN developed in 4 nontransplanted patients.
CONCLUSION CONCLUSIONS
Transplanted females had high HR-HPV, abnormal cervical cytology and CIN prevalence rates compared to large published cohorts in the general non-CF population. Although HR-HPV prevalence and persistence were globally not significantly different in nontransplanted females compared to the general population, we reported high frequencies of abnormal cytology and CIN. Cervical cancer screening and prevention should be promoted among females with CF.

Identifiants

pubmed: 36526553
pii: S1569-1993(22)01415-1
doi: 10.1016/j.jcf.2022.11.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

505-514

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

C Rousset-Jablonski (C)

Hospices Civils de Lyon (HCL), Cystic Fibrosis Adult Refence Center, Department of Internal Medicine, Groupe Hospitalier Sud, 69495 Pierre Benite Cedex, France; Hospices Civils de Lyon. Department of Obstetrics and Gynecology, Groupe Hospitalier Sud, 69495 Pierre Benite Cedex, France; Leon Berard Cancer Center. Department of Surgical Oncology, Centre Léon Bérard, 28 rue Laënnec, 69008 Lyon, France; INSERM U1290 RESHAPE Research in Health Care Performance, Lyon 1 Claude Bernard University, Lyon, France. Electronic address: christine.rousset-jablonski@chu-lyon.fr.

Y Mekki (Y)

Hospices Civils de Lyon, Laboratory of Virology IAI, Lyon, France.

A Denis (A)

Hospices Civils de Lyon, Pôle de Santé Publique -Service de Recherche et d'Epidémiologie Cliniques. Groupement Hospitalier Est. 59 Boulevard Pinel - 69677 Bron Cedex, France.

Q Reynaud (Q)

Hospices Civils de Lyon (HCL), Cystic Fibrosis Adult Refence Center, Department of Internal Medicine, Groupe Hospitalier Sud, 69495 Pierre Benite Cedex, France; INSERM U1290 RESHAPE Research in Health Care Performance, Lyon 1 Claude Bernard University, Lyon, France.

R Nove-Josserand (R)

Hospices Civils de Lyon (HCL), Cystic Fibrosis Adult Refence Center, Department of Internal Medicine, Groupe Hospitalier Sud, 69495 Pierre Benite Cedex, France.

S Durupt (S)

Hospices Civils de Lyon (HCL), Cystic Fibrosis Adult Refence Center, Department of Internal Medicine, Groupe Hospitalier Sud, 69495 Pierre Benite Cedex, France.

S Touzet (S)

INSERM U1290 RESHAPE Research in Health Care Performance, Lyon 1 Claude Bernard University, Lyon, France; Hospices Civils de Lyon, Pôle de Santé Publique -Service de Recherche et d'Epidémiologie Cliniques. Groupement Hospitalier Est. 59 Boulevard Pinel - 69677 Bron Cedex, France.

M Perceval (M)

Hospices Civils de Lyon (HCL), Cystic Fibrosis Adult Refence Center, Department of Internal Medicine, Groupe Hospitalier Sud, 69495 Pierre Benite Cedex, France.

I Ray-Coquard (I)

Leon Berard Cancer Center, Departement of medical oncology, Centre Léon Bérad, 28 rue Laënnec, 69008 Lyon.

F Golfier (F)

Hospices Civils de Lyon. Department of Obstetrics and Gynecology, Groupe Hospitalier Sud, 69495 Pierre Benite Cedex, France.

I Durieu (I)

Hospices Civils de Lyon (HCL), Cystic Fibrosis Adult Refence Center, Department of Internal Medicine, Groupe Hospitalier Sud, 69495 Pierre Benite Cedex, France; INSERM U1290 RESHAPE Research in Health Care Performance, Lyon 1 Claude Bernard University, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH